This is the authors' abstract. We don't add key points for this paper.
Coenzyme F 420 is a specialized redox cofactor with a highly negative redox potential. It supports biochemical processes like methanogenesis, degradation of xenobiotics or the biosynthesis of antibiotics. Although well-studied in methanogenic archaea and actinobacteria, not much is known about F 420 in Gram-negative bacteria. Genome sequencing revealed F 420 biosynthetic genes in the Gram-negative, endofungal bacterium Paraburkholderia rhizoxinica , a symbiont of phytopathogenic fungi. Fluorescence microscopy, high-resolution LC-MS, and structure elucidation by NMR demonstrated that the encoded pathway is active and yields unexpected derivatives of F 420 (3PG-F 420 ). Further analyses of a biogas-producing microbial community showed that these derivatives are more widespread in nature. Genetic and biochemical studies of their biosynthesis established that a specificity switch in the guanylyltransferase CofC re-programmed the pathway to start from 3-phospho-D-glycerate, suggesting a rerouting event during the evolution of F 420 biosynthesis. Furthermore, the cofactor activity of 3PG-F 420 was validated, thus opening up perspectives for its use in biocatalysis. The 3PG-F 420 biosynthetic gene cluster is fully functional in Escherichia coli , enabling convenient production of the cofactor by fermentation.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Braga et al. (2019) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: